ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, has confirmed that it will be announcing its Interim results for the six months ended 30 June 2017 on Wednesday 27 September 2017.
ImmuPharma PLC is a drug discovery and development company. The Company is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The Company has approximately five drug candidates in development, over two platform technologies and approximately 70 patents. Lupuzor is the Company’s drug candidate and is a treatment for lupus, and life threatening auto immune disease.